Neurological syndrome after R-CHOP chemotherapy for a non-Hodgkin lymphoma: what is the diagnosis?
- PMID: 21993875
- DOI: 10.1007/s12185-011-0942-4
Neurological syndrome after R-CHOP chemotherapy for a non-Hodgkin lymphoma: what is the diagnosis?
Abstract
A 63-year-old man was admitted to our Oncology department for management of a follicular non-Hodgkin lymphoma, stage IV A FLIPI 5. The patient entered chemotherapy following the R-CHOP schedule, and a PET scan after three cycles showed partial remission. One week later he was admitted to our hospital after developing serious pain in his left arm resulting in an impaired function, right facial hemiplegia, and ophthalmoplegia. Neuroimaging studies and laboratory features were negative. Given his symptoms, we suspected Miller Fisher syndrome and the patient was administered high dose immunoglobulin, but showed no improvement. Finally, chemotherapy with methotrexate 3 g/mq was initiated, but his condition progressively worsened and the patient died 2 months later. We suggest that any patient with neurological symptoms who has received rituximab should undergo PCR analysis for all neurotropic viruses together with neurophysiological and neuroimaging studies.
Similar articles
-
[Supportive care for patients with non-Hodgkin lymphoma receiving R-CHOP chemotherapy].Nihon Rinsho. 2015 Feb;73 Suppl 2:636-41. Nihon Rinsho. 2015. PMID: 25831838 Japanese. No abstract available.
-
Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.Ann Hematol. 2013 Jan;92(2):231-8. doi: 10.1007/s00277-012-1592-1. Epub 2012 Oct 10. Ann Hematol. 2013. PMID: 23053189 Free PMC article.
-
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
-
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.Lancet Haematol. 2020 Apr;7(4):e295-e308. doi: 10.1016/S2352-3026(20)30031-4. Epub 2020 Mar 2. Lancet Haematol. 2020. PMID: 32135128
-
Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.Br J Haematol. 2012 Oct;159(1):39-49. doi: 10.1111/j.1365-2141.2012.09247.x. Epub 2012 Jul 31. Br J Haematol. 2012. PMID: 22849793 Review.
Cited by
-
Biological Drugs in Guillain-Barré Syndrome: An Update.Curr Neuropharmacol. 2017;15(7):938-950. doi: 10.2174/1570159X14666161213114904. Curr Neuropharmacol. 2017. PMID: 27964705 Free PMC article. Review.
-
REFRACTORY GUILLAIN-BARRÉ SYNDROME IN A PATIENT WITH ASYMPTOMATIC MULTIPLE MYELOMA SUCCESSFULLY TREATED WITH LOW-DOSE RITUXIMAB.Acta Clin Croat. 2023 Aug;62(2):382-386. doi: 10.20471/acc.2023.62.02.19. Acta Clin Croat. 2023. PMID: 38549594 Free PMC article.
-
Intravascular Large B-Cell Lymphoma Diagnosed After Recurrent Stroke: Case Report and Literature Review.Neurol Int. 2025 Apr 27;17(5):68. doi: 10.3390/neurolint17050068. Neurol Int. 2025. PMID: 40423224 Free PMC article.
-
Utility of Brainstem Auditory Evoked Response as a Diagnostic Tool and Rituximab as a Treatment for Severe Bickerstaff Brainstem Encephalitis: A Case Report.Cureus. 2024 Apr 10;16(4):e57993. doi: 10.7759/cureus.57993. eCollection 2024 Apr. Cureus. 2024. PMID: 38738130 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials